Mitchell Mcleod Pugh & Williams Inc. held its stake in shares of Celgene Corporation (NASDAQ:CELG) during the second quarter, Holdings Channel reports. The fund owned 6,750 shares of the biopharmaceutical company’s stock at the end of the second quarter. Mitchell Mcleod Pugh & Williams Inc.’s holdings in Celgene Corporation were worth $877,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. Diversified Trust Co increased its stake in shares of Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock valued at $291,000 after buying an additional 9 shares during the last quarter. Sowell Financial Services LLC increased its stake in shares of Celgene Corporation by 0.5% in the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 13 shares during the last quarter. South Texas Money Management Ltd. increased its stake in shares of Celgene Corporation by 0.6% in the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 15 shares during the last quarter. Flagship Harbor Advisors LLC increased its stake in shares of Celgene Corporation by 0.9% in the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 18 shares during the last quarter. Finally, Keel Point LLC increased its stake in shares of Celgene Corporation by 0.9% in the first quarter. Keel Point LLC now owns 3,103 shares of the biopharmaceutical company’s stock valued at $386,000 after buying an additional 28 shares during the last quarter. Hedge funds and other institutional investors own 78.41% of the company’s stock.

Celgene Corporation (NASDAQ:CELG) traded down 3.02% during mid-day trading on Thursday, hitting $131.47. 1,311,764 shares of the stock traded hands. Celgene Corporation has a 12 month low of $96.93 and a 12 month high of $139.00. The stock’s 50 day moving average is $134.30 and its 200-day moving average is $124.13. The company has a market cap of $102.86 billion, a price-to-earnings ratio of 40.72 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the prior year, the firm earned $1.44 EPS. The firm’s quarterly revenue was up 18.7% compared to the same quarter last year. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Mitchell Mcleod Pugh & Williams Inc. Holds Position in Celgene Corporation (NASDAQ:CELG)” was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/mitchell-mcleod-pugh-williams-inc-holds-position-in-celgene-corporation-nasdaqcelg/1471345.html.

Several equities research analysts have recently weighed in on the company. Jefferies Group LLC set a $154.00 price target on Celgene Corporation and gave the stock a “buy” rating in a report on Saturday, May 13th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and increased their price target for the stock from $96.93 to $131.70 in a report on Friday, June 30th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 price target on shares of Celgene Corporation in a report on Wednesday. Robert W. Baird reissued an “outperform” rating and issued a $162.00 price objective on shares of Celgene Corporation in a research note on Monday, May 22nd. Finally, SunTrust Banks, Inc. set a $150.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, July 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and twenty-three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $147.06.

In other Celgene Corporation news, insider Rupert Vessey sold 4,785 shares of the stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the sale, the insider now owns 4,004 shares of the company’s stock, valued at approximately $481,200.72. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Gilla Kaplan sold 7,500 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the sale, the director now directly owns 76,301 shares in the company, valued at approximately $10,264,010.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 235,255 shares of company stock worth $31,377,042. Insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.